Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 9/2001

01-09-2001 | Review Article

Impact of Allergic Rhinitis Treatment on Quality of Life

Authors: Dr Anju Tripathi, Roy Patterson

Published in: PharmacoEconomics | Issue 9/2001

Login to get access

Abstract

Allergic rhinitis is a chronic inflammatory disorder of the nasal passages. It affects approximately 20% of the population, is a significant health and economic burden, and severely impairs quality of life.
Two main instruments, Medical Outcomes Study 36-Item Short Form health survey (SF-36) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) have been used to assess quality of life in patients with allergic rhinitis. Antihistamines, corticosteroids, anticholinergic agents, decongestants, cromoglycates, and immunotherapy are used to treat patients with allergic rhinitis.
Of these, antihistamines and intranasal corticosteroids are the most efficacious and frequently utilised medications. Studies have demonstrated improvements in quality of life with both of these medications in patients with allergic rhinitis.
Literature
1.
Druce HM. Allergic and nonallergic rhinitis. In: Middleton EJ, Reed CE, Ellis EF, et al., editors. Allergy principles and practice. 5th ed. St. Louis: Mosby Year Book Inc., 1998: 1005–16
2.
Emmanuel EB. Hayfever, a post-industrial revolution epidemic: a history of its growth during the 19th century. Clin Allergy 1988; 18: 295–304CrossRef
3.
4.
Barbee R, Kaltenborn W, Lebowitz M, et al. Longitudinal changes in skin test reactivity in a community population sample. J Allergy Clin Immunol 1987; 79: 16–24PubMedCrossRef
5.
Upton MN, McConnachie A, McSharry C, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ 2000; 321 (7253): 88–92PubMedCrossRef
6.
Ciprandi G, Vizzaccaro A, Cirillo I, et al. Increase of asthma and allergic rhinitis prevalence in young Italian men. Int Arch All Immunol 1996; 111 (3): 278–83CrossRef
7.
Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: Complete Guidelines of the Joint Task Force on practice parameters in allergy, asthma, and immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518PubMedCrossRef
8.
Malone DC, Battista C, Arrighi HM, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99: 22–7PubMed
9.
10.
Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile: development of an outcome measure for health care. Am J Public Health 1975; 65: 1304PubMedCrossRef
11.
Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994; 94: 182–8PubMedCrossRef
12.
Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77–83PubMedCrossRef
13.
Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjuncitivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994; 93: 413–23PubMedCrossRef
14.
Meltzer EO, Nathan RA, Selner JC, et al. Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 1997; 99 (Pt 2): S815–9CrossRef
15.
Guill MF, Buckley RH, Rocha W, et al. Multicenter, double-blind, placebo-controlled trial of terfenadine suspension in the treatment of fall-allergic rhinitis in children. J Allergy Clin Immunol 1986; 78: 4–9PubMedCrossRef
16.
Georgitis JW, Shen D. Nasal pharmacodynamics of brompheniramine in perennial rhinitis. Arch Otolaryngol Head Neck Surg 1988; 114: 63–7PubMedCrossRef
17.
Dockhorn RJ, Bergner A, Connell JT, et al. Safety and efficacy of loratidine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. Ann Allergy 1987; 58: 407–11PubMed
18.
Backhouse CI, Renton R, Fidler C, et al. Multicentre double-blind comparison of terfenadine and cetirizine in patientswith seasonal allergic rhinitis. Br J Clin Pract 1990; 44: 88–91PubMed
19.
20.
Druce H. Impairment of function by antihistamines. Ann Allergy 1990; 64: 403–5PubMed
21.
O’Hanlon JF. Antihistamines and driving performance: The Netherlands. J Respir Dis 1988; 9: 12–7
22.
Roth T, Roehrs T, Koshorek G, et al. Sedative effects of antihistamines. J Allergy Clin Immunol 1987; 80: 94–8PubMedCrossRef
23.
Nolan TM. Sedative effects of antihistamines: safety, performance, learning, and quality of life. Clin Ther 1997; 19 (1): 39–55CrossRef
24.
Vuurman EFPM, van Veggel LMA, Uiterwijk MMC, et al. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy 1993; 71: 121–6PubMed
25.
Zyrtec® (cetirizine hydrochloride) tablets. Physicians’ Desk Reference. Montvale (NJ): Medical Economics Co, Inc., 2000: 2405
26.
Ramaekers JG, Uiterwijk MMC, O’Hanlon JF. Effects of loratidine and cetirizine on actual driving a psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992; 42: 363–9PubMed
27.
Patat A, Stubbs D, Dunmore C, et al. Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects. Eur J Clin Pharmacol 1995; 48: 143–50PubMedCrossRef
28.
Volkerts ER, van Willigenburg PP, van Laar MW, et al. Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects of highway driving, psychometric test performance and daytime sleepiness. Hum Psychopharmacol 1992; 7: 227–38CrossRef
29.
Kemp JP. Antihistamines: is there anything safe to prescribe? Ann Allergy 1992; 69: 276–80PubMed
30.
Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratidine and promethazine on cognitive and psychomotor function. Br J Clin Pharm 1999; 48 (2): 200–6CrossRef
31.
Honig PK, Worthoun DC, Zamani K, et al. Terfenadine-ketoconazole interaction. JAMA 1993; 269: 1513–8PubMedCrossRef
32.
Tobin JR, Doyle TP, Ackerman AD, et al. Astemizole-induced cardiac conduction disturbances in a child. JAMA 1991; 266: 2737–40PubMedCrossRef
33.
Brannan MD, Reidenberg P, Radwanski E, et al. Loratidine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmcol Ther 1995; 58: 269–78CrossRef
34.
Sale M, Woosley R, Thakker K, et al. Effects of cetirizine and erythromycin, alone and in combination on QT interval and pharmacokinetics in healthy subjects [abstract]. Ann Allergy Asthma Immunol 1996; 76: 93
35.
Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 443–8PubMedCrossRef
36.
Bousquet J, Duchateau J, Pignat JC, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French Version of the SF-36 questionnaire. J Allergy Clin Immunol 1996; 98: 308–16
37.
Meltzer EO, Casale TB, Nathan RA, et al. Once-daily fexofenadine HCL improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 311–7PubMedCrossRef
38.
Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratidine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100: 781–8PubMedCrossRef
39.
Janssens MML, Bussche GV. Levocarbastine: an effective topical treatment of allergic rhinoconjunctivitis. Clin Exp Allergy 1991; 21 Suppl. 2: 29–36PubMedCrossRef
40.
Ratner PH, Findlay SR, Hampel Jr F, et al. A double-blind controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol 1994; 94: 818–25PubMedCrossRef
41.
Astelin® (azelastine hydrochloride) nasal spray. Physicians’ Desk Reference. Montvale (NJ): Medical Economics Co., Inc., 2000: 3148
42.
Busse W, Randley B, Sedgwick J, et al. The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol 1989; 83: 400–5PubMedCrossRef
43.
Ciprandi G, Pronzati C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996; 98: 1088–96PubMedCrossRef
44.
Pichler WJ, Klint T, Blaser G, et al. Clinical comparison of systemic methylprednisolone acetate versus topical budesonide in patients with seasonal allergic rhinitis. Allergy 1988; 43 (2): 87–92PubMedCrossRef
45.
Ratner P, van Bavel J, Gross G, et al. New formulation of aqueous flunisolide nasal spray in the treatment of allergic rhinitis: comparative assessment of safety, tolerability, and efficacy. Allergy Asthma Proc 1996: 17 (3): 149–56PubMedCrossRef
46.
Hillas J, Booth RJ, Somerfield S, et al. A comparative trial of intra-nasal beclomethasone dipropionate and sodium cromoglycate in patients with chronic perennial rhinitis. Clin Allergy 1980; 10: 253–8PubMedCrossRef
47.
Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987; 62: 125–34PubMedCrossRef
48.
Bernstein DI, Creticos PS, Busse WW, et al. Comparison of triamcinolone acetonide nasal inhaler with astemizole in treatment of ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996; 97: 749–55PubMedCrossRef
49.
Bronsky EA, Dockhorn RJ, Meltzer EO, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 749–55CrossRef
50.
Gomez E, Clague JE, Gatland D, et al. Effect of topical corticosteroids on seasonally induced increases in nasal mast cells. BMJ 1988; 296: 1572–3PubMedCrossRef
51.
Rak S, Jacobson MR, Sudderick RM, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994; 24: 930–9PubMedCrossRef
52.
Laforce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 1999; 103 (Suppl. Pt 2): S388–94PubMedCrossRef
53.
LaForce C, Davis V. Nasal septal perforation in patients using intranasal beclomethasone propionate (BDP) [abstract]. J Allergy Clin Immunol 1985; 75 Suppl.: 186CrossRef
54.
Soedber Warner ML. Nasal septal perforation associated with topical corticosteroid therapy. J Pediatr 1984; 105: 840–1CrossRef
55.
Halopainen E, Mlmberg H, Binder E. Long term follow-up of intra-nasal beclomethasone treatment: a clinical and histologic study. Acta Otolaryngol 1982; 386 Suppl.: 270CrossRef
56.
Sorensen H, Mygind N, Pederson CB, et al. Long term treatment of nasal polyps with beclomethasone dipropionate aerosol. III. Morphological studies and conclusions. Acta Otolaryngol 1976; 182: 260–2CrossRef
57.
Orgel HA, Meltzer EO, Bierman CW, et al. Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy and safety study including nasal biopsy. J Allergy Clin Immunol 1991; 88: 257–64PubMedCrossRef
58.
Rachelefsky GS, Chervinsky P, Meltzer EO, et al. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray on long-term growth in children [abstract]. J Allergy Clin Immunol 1998; 101 (Pt 2): S236
59.
Wolthers OD, Pedersen S. Short term growth in children with allergic rhinitis treated with oral antihistamine depot and intranasal glucocorticosteroids. Acta Pediatr 1993; 82: 635–40
60.
Wiseman LR, Benfield P. Intranasal fluticasone propionate: a reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997; 53: 885–907PubMedCrossRef
61.
Brannan MD, Herron JM, Reidenberg P, et al. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther 1995; 17 (4): 637–47PubMedCrossRef
62.
Pipkorn U, Pukander J, Suonpaa J, et al. Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin Allergy 1988; 18: 253–9PubMedCrossRef
63.
Juniper EF, Willms DG, Guyatt GH, et al. Aqueous beclomethasone dipropionate nasal spray in the treatment of seasonal (ragweed) rhinitis. CMAJ 1992; 147 (6): 887–92PubMed
64.
Juniper EF, Guyatt GH, O’Byrne PM, et al. Aqueous beclomethasone dipropionate nasal spray: regular versus ‘as required’ use in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1990; 86: 380–6PubMedCrossRef
65.
Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998; 81: 128–34PubMedCrossRef
66.
Shapiro GG, Konig P. Cromolyn sodium: a review. Pharmacotherapy 1985; 5: 156–70PubMed
67.
Schulller DE, Fink JN, Fillery WV, et al. A multicenter trial of nedocromil sodium, 1% nasal solution, compared with cromolyn sodium and placebo in ragweed seasonal allergic rhinitis. J Allergy Clin Immunol 1990; 86: 554–61CrossRef
68.
Juniper EF, Guyatt GH, Ferrie PJ, et al. Sodium cromoglycate eye drops: regular versus ‘as needed’ use in the treatment of seasonal allergic conjunctivitis. J Allergy Clin Immunol 1994; 94 (1): 36–43PubMedCrossRef
69.
Meltzer EO, Orgel A, Bronsky EA, et al. Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: a study of its effect on their symptoms, quality of life, and nasal cytology. J Allergy Clin Immunol 1992; 90: 242–9PubMedCrossRef
70.
Grossman J, Banov C, Boggs P, et al. Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. J Allergy Clin Immunol 1995; 95: 1123–7PubMedCrossRef
71.
Williams BO, Hull H, McSorley P. Efficacy of acrivastine plus pseudoephedrine for symptomatic relief of seasonal allergic rhinitis due to mountain cedar. Ann AllergyAsthma Immunol 1996; 76: 432–8CrossRef
72.
Bronsky E, Poggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratidine-pseudoephedrine combination versus components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 1995; 96; 139–47PubMedCrossRef
73.
Durham SF, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468–75PubMedCrossRef
74.
Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997; 100: 293–300PubMedCrossRef
75.
Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patient swith grass pollen rhinitis. Allergy 1988; 43: 523–9PubMedCrossRef
76.
77.
Fell WR, Mabry RL, Mabry CS. Quality of life analysis of patients undergoing immunotherapy for allergic rhinitis. Ear Nose Throat J 1997; 76 (8): 528–36PubMed
78.
Juniper EF, Guyatt GH, Griffith LE. First-line treatment of seasonal (ragweed) rhinoconjunctivitis: a randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine. CMAJ 1997; 156 (8): 1123–31PubMed
79.
Ratner PH, van Bavel JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratidine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998; 47 (2): 118–25PubMed
80.
Kozma CM, Schulz RM, Sclar DA, et al. A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis. Clin Ther 1996; 18: 334–46PubMedCrossRef
81.
Munch EP, Soborg M, Norreslet TT, et al. A comparative study of dexchlorphenirmaine maleate sustained release tablets and budesonide nasal spray in seasonal allergic thinitis. Allergy 1983; 38: 517–24PubMedCrossRef
82.
Schoenwetter W, Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis. Clin Ther 1995; 17: 479–92PubMedCrossRef
83.
Dickson DJ, Crucickshank MJ. Comparison of flunisolide nasal spray and terfenadine tablets in hay fever. Br J Clin Pract 1984; 416–20
84.
van Bavel J, Findlay SR, Hampel Jr FC, et al. Intranasal fluticasone propionate is nore effective than terfenadine tablets for seasonal allergic rhintis. Arch Intern Med 1994; 154: 2699–704PubMedCrossRef
85.
Gehanno P, Desfougheres J-L. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy 1997; 52: 445–50PubMedCrossRef
86.
Beswick KBJ, Kenyon GS, Cherry JR. A comparative study of beclomethasone dipropionate aqueous spray with terfenadine tablets in seasonal allergic rhinitis. Curr Med Res Opin 1985; 9: 560–7PubMedCrossRef
87.
Bjerrum P, Illum P. Treatment of seasonal allergic rhinitis with budesonide and disodium cromoglycate. Allergy 1985; 40: 65–9PubMedCrossRef
88.
Brooks CD, Francom SF, Peel BG, et al. Spectrum of seasonal allergic rhinitis symptom relief with topical corticoid and oral antihistamine given singly or in combination. Am J Rhinology 1996; 10: 193–9CrossRef
Metadata
Title
Impact of Allergic Rhinitis Treatment on Quality of Life
Authors
Dr Anju Tripathi
Roy Patterson
Publication date
01-09-2001
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 9/2001
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200119090-00001

Other articles of this Issue 9/2001

PharmacoEconomics 9/2001 Go to the issue

Original Research Article

Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden

Original Research Article

The Economics of HIV Vaccines

Original Research Article

Different Approaches To Valuing the Lost Productivity of Patients with Migraine

Original Research Article

Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke

Original Research Article

The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong

Original Research Article

A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy